Skip to main content
Clinical Trials/NCT01862289
NCT01862289CompletedNot Applicable

Prevalence of Hyperventilation Syndrome in Difficult Asthmatics Uncontrolled Despite a Daily Maximal Doses of Inhaled Treatment

Assistance Publique - Hôpitaux de Paris2 sites in 1 country151 target enrollmentStarted: April 28, 2013Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
151
Locations
2
Primary Endpoint
Diagnostic of the hyperventilation syndrome

Study Overview

Brief Summary

Most of asthmatics patients remain uncontrolled despite an inhaled steroids treatment. Chronic hyperventilation syndrome (also called Idiopathic Hyperventilation) occurs in 20 to 40% of asthmatic patients. The purpose of the study is to assess the prevalence of chronic hyperventilation syndrome in a specific population of difficult-to-treat asthmatics patients, those who receive daily high doses of inhaled steroids (≥ 1000 µg of fluticasone with an additional treatment by a long-acting beta 2-agonist (LABA) and who remain uncontrolled (Asthma control test (ACT) < 18). We plan to realize a systematic assessment of the diagnosis of chronic hyperventilation syndrome with the Nijmegen questionnaire, blood gases at rest, hyperventilation testing and Cardiopulmonary Exercise Testing(CPET). We also will collect demographic information as well as information about asthma history, asthma control and treatment.

Detailed Description

There is only one visit. During this visit, each patient will complete self-questionnaires like Nijmegen, Hospital Anxiety and Depression Scale(HAD), Short-Form 36(SF36), and Asthma Quality of Life Questionnaire (AQLQ), The participants will have baseline spirometry and fractional exhaled nitric oxide measured at expiratory flow of 50 mL/s (FENO50), blood gases at rest, an hyperventilation challenge and Cardiopulmonary Exercise Testing(CPET) to determine accurately the presence or not of chronic hyperventilation syndrome. The diagnosis is confirmed by two positive tests (Nijmegen, Hyperventilation challenge and blood gases) and the final decision of a medical committee. The first step is to determine the prevalence oh this syndrome in this specific population. The second step is to assess the sensitivity, the specificity, the false positive rate and the false negative rate of the different parameters measured during the tests.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Diagnostic
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • men and women,
  • aged more than 18,
  • non smokers for two years or longer, less than 10 pack/years smoking history,
  • physician-diagnosed asthma,
  • uncontrolled asthma with Asthma control test (ACT) < 18,
  • historical of FEV1 reversibility,
  • daily inhaled steroids treatment by at least 2000microg eq beclomethasone,
  • Forced expiratory volume in 1 second (FEV1) > 50% predicted value

Exclusion Criteria

  • other chronic pulmonary disease,
  • vocal cord dysfunction,
  • pregnancy,
  • Participation in another interventional research trial,
  • unable to provide consent,
  • asthma exacerbation within the last 4 weeks

Arms & Interventions

Severe uncontrolled asthma

Experimental

Asthmatics patients with uncontrolled symptoms despite a daily treatment by high doses of inhaled steroids and LABA. Diagnostic of chronic hyperventilation syndrome.

Intervention: Diagnostic of chronic hyperventilation syndrome (Other)

Outcomes

Primary Outcomes

Diagnostic of the hyperventilation syndrome

Time Frame: Up to 4 hours

value of Nijmegen questionnaire, of blood gases at rest, of hyperventilation testing and of CPET

Secondary Outcomes

  • Assess the diagnosis value of the nijmegen questionnaire.(Up to 4 hours)
  • Assess the diagnosis value of the blod gases at rest.(up to 4 hours)
  • Assess the diagnosis value of the hyperventilation challenge.(Up to 4 hours)
  • Assess the diagnosis value of the CPET.(Up to 4 hours)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials